A number of factors such as the growing awareness among youth about alcohol and drug addiction problems, surging technological advancements in drug of abuse (DOA) testing products, and soaring implementation of government initiatives for reducing the consumption of illicit drug use will drive the European DOA testing market at a CAGR of 9.6% during the forecast period (2018–2023). According to P&S Intelligence, the market reached a revenue of $1.7 billion in 2017, and it is projected to generate $3.0 billion revenue by 2023. 

The market growth is primarily dependent on the mounting awareness about excessive drug and alcohol consumption. People in the Eastern parts of Europe consume a considerable volume of alcohol due to their high disposable income. The increasing consumption of this beverage in Eastern Europe is accelerating the disability and mortality rates in this part of the continent. People residing in the countries near the Russian Federation are the largest consumers of alcohol in Europe.   

The offering segment of the European DOA testing market is bifurcated into products and services. Of these, the products category generated the higher revenue in 2017, due to the soaring awareness about DOA testing devices and the increasing number of technologically advanced products in Europe. Whereas, the services category is expected to witness the faster growth during the forecast period, due to the rising practice of drug testing at workplaces and the burgeoning focus of market players on providing technologically advanced products to the European populace.

Browse detailed report - Europe Drug of Abuse (DOA) Testing Market Analysis and Demand Forecast Report

Geographically, the U.K. accounted for the largest share in the European DOA testing market in 2017, and it is also expected to exhibit the fastest growth throughout the forecast period. This can be credited to the surging incidence of drug abuse and escalating awareness about DOA testing in the country. According to the Office for National Statistics, cannabis was the most common drug used among the people of the U.K. between March 2019 and March 2020. In the country, around 7.8% of individuals within the age group of 16–59 years were using this drug during the same period.  

Therefore, the rising awareness about drug and alcohol-related problems and increasing availability of technologically enhanced DOA testing products will facilitate the market growth in the foreseeable future.